Antimyoclonic action of piracetam.

Five patients with myoclonus were treated with oral piracetam (8-9 g/day). All patients had action-sensitive and/or stimulus-sensitive myoclonus and enhanced amplitude of somatosensory evoked potentials. Piracetam produced a marked reduction of the myoclonus in the five subjects without side effects. In view of its excellent tolerance and synergism with other antimyoclonic drugs, we consider piracetam to be a very valuable drug for the treatment of patients with myoclonus of any origin.